“In the few months Jeffrey has been on the Intec Board he established himself as a strong, insightful leader and made significant contributions to our company. We are delighted to appoint him as Chief Executive Officer and extend thanks to Giora for stepping in to serve as interim CEO,” commented John W. Kozarich, Ph.D., Chairman of the Board of Intech Pharma.
“We look forward to building a U.S. presence under Jeffrey’s stewardship while advancing our Accordion Pill platform technology in a number of therapeutic indications. In particular, as we near the completion of a pivotal Phase 3 clinical trial of our Accordion Pill Carbidopa/Levodopa, Jeffrey’s considerable industry experience should enhance our pre-commercialization strategies to maximize the potential of the Accordion Pill in Parkinson’s disease,” he added. “Importantly, Jeffrey’s strategic planning and business development skills make him uniquely qualified to expand our platform technology in various indications and to enhance the